Consensus Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
3.93 ^USD	+0.77%		-12.67%	+94.55%

Apr. 12	Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology	CI
Apr. 11	Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target	MT

Evolution of the average Target Price on Aquestive Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

338247355.yM-4g_mKdKLp_tqOOmV4Kg53KVWFoOFebtzvNVxxUOY.svz_z6voLOeTue26UDIMemYcHCb295AEJey1TQ0kOI2YieH5nvxH4IrLjw~83b87fbe39acc45b250128699acec3b8

Analyst Recommendations on Aquestive Therapeutics, Inc.

Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target	Apr. 11	MT
Raymond James Initiates Aquestive Therapeutics With Outperform Rating, $7 Price Target	Mar. 28	MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering	Mar. 20	MT
H.C. Wainwright Raises Price Target on Aquestive Therapeutics to $9 From $7, Maintains Buy Rating	Mar. 18	MT
JMP Securities Adjusts Price Target on Aquestive Therapeutics to $10 From $8, Maintains Market Outperform Rating	Mar. 15	MT
HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $7 From $6, Maintains Buy Rating	Mar. 11	MT
Wedbush Lifts Aquestive Therapeutics' PT to $9 From $4 After Model Adjustments, Keeps Outperform Rating	Mar. 07	MT
HC Wainwright Raises Price Target on Aquestive Therapeutics to $6 From $5, Maintains Buy Rating	Nov. 08	MT
Wedbush Lifts Aquestive Therapeutics' Price Target to $4 From $3 Due to Decreased Share Count, Keeps Outperform Rating	23-08-10	MT
Wedbush Trims Aquestive Therapeutics' PT to $3 From $4, Pushes US, EU Launch Estimates for Anaphylm/Anaphylaxis; Keeps Outperform Rating	23-07-03	MT
Wedbush Upgrades Aquestive Therapeutics to Outperform Rating From Neutral, Adjusts Price Target to $4 From $3	23-03-09	MT
Wedbush Downgrades Aquestive Therapeutics to Neutral From Outperform, Notes Limited Cash Runway; Trims Price Target to $3 From $4	23-01-31	MT
Alliance Global Partners Adjusts Price Target on Aquestive Therapeutics to $7 From $10, Maintains Buy Rating	22-11-04	MT
Oppenheimer Initiates Coverage on Aquestive Therapeutics With Outperform Rating, $8.50 Price Target	22-09-07	MT
HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $5 From $6, Reiterates Buy Rating	22-09-06	MT
BMO Capital Adjusts Aquestive Therapeutics' Price Target to $6 from $9, Maintains Outperform Rating	22-09-01	MT
Alliance Global Initiates Aquestive Therapeutics at Buy Rating With $10 Price Target	22-08-30	MT
Wedbush Adjusts Price Target on Aquestive Therapeutics to $4 From $8 on Potential Share Count Increase; Outperform Rating Kept	22-08-04	MT
HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $5 From $8, Reiterates Buy Rating	22-06-21	MT
HC Wainwright Adjusts Aquestive Therapeutics' Price Target to $8 From $14, Keeps Buy Rating	22-05-31	MT
Wedbush Adjusts Aquestive Therapeutics' Price Target to $8 From $26, Removes Libervant From Pipeline Valuation; Outperform Rating Kept	22-03-10	MT
Wedbush Trims Aquestive Therapeutics' Price Target to $26 From $28 on Libervant Launch Timeline; Outperform Rating Kept	21-12-22	MT
AQUESTIVE THERAPEUTICS : Wedbush Adjusts Price Target on Aquestive Therapeutics to $28 From $30, Keeps Outperform Rating	21-08-05	MT
AQUESTIVE THERAPEUTICS : Wedbush Adjusts Price Target on Aquestive Therapeutics to $30 From $32 on Stock Dilution, Keeps Outperform Rating	21-03-11	MT
AQUESTIVE THERAPEUTICS : Wedbush Adjusts Price Target for Aquestive Therapeutics to $32 From $31, Maintains Outperform Rating	20-11-10	MT